This article is more than 5 years old. Information may no longer be current.
MMR booster failed to increase JIA disease activity in children
Click Here to Manage Email Alerts
The measles-mumps-rubella vaccination in children with juvenile idiopathic arthritis compared with no booster did not result in worsened juvenile idiopathic arthritis disease activity and was immunogenic, according to recent study findings published in The Journal of the American Medical Association.
“Patients with [juvenile idiopathic arthritis] may be susceptible to infections through the immunosuppressive effect of their disease or its treatment,” researchers wrote. “Preventing infections in patients with [juvenile idiopathic arthritis] requires effective and safe vaccinations that induce protective immune responses, have no severe adverse effects, and do not affect [juvenile idiopathic arthritis] disease activity.”
The randomized, multicenter, open-label clinical equivalence trial included 137 children with juvenile idiopathic arthritis (JIA) aged 4 to 9 years. Participants were randomly assigned (MMR) booster vaccination or no vaccination.
Researchers found that disease activity did not differ between 63 revaccinated participants during complete follow-up, as measured by the Juvenile Arthritis Disease Activity Score including 27 joints (JADAS-27=2.8; 95% CI, 2.1-3.5), and 68 controls (JADAS-27=2.4; 95% CI, 1.7-3.1). Revaccinated participants had higher seroprotection rates at 12 months vs. the controls for measles (100% vs. 92%, respectively), mumps (97% vs. 81%) and rubella (100% vs. 94%). Antibody concentrations also were higher in revaccinated participants vs. the controls against measles (1.63 IU/mL vs. 0.78 IU/mL; P=.03), mumps (168 RU/mL vs. 104 RU/mL; P=.03) and rubella (69 IU/mL vs. 45 IU/mL; P=.01).
“In this randomized trial, MMR booster vaccination did not result in a significant difference in JIA disease activity and was immunogenic in patients with JIA,” researchers wrote. “Vaccination generated high seroprotection rates (97%-100%) and a sustained increase in MMR-specific antibodies.”
Disclosure: The study was funded by the Dutch Arthritis Association. See the study for a full list of disclosures.
Collapse
Click Here to Manage Email Alerts